INTEGRATED BIOPHARMA INC financials

INBP CIK 0001016504

Source: EDGAR filings · Built 2026-09-29T00:05:53Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Free Cash Flow 850.00K 1.87M 348.00K 1.08M 3.60M 2.68M
EBITDA -2.41M 2.34M 558.00K 471.00K 3.08M 6.12M
Working Capital 11.58M 14.52M 11.75M 11.54M 11.36M 8.76M
Net Debt -1.39M -2.60M 121.00K 1.41M 1.64M 5.80M
Gross Margin 1.82% 10.23% 7.72% 8.01% 11.65% 14.92%
Operating Margin -6.17% 3.72% 0.50% 0.24% 4.88% 9.10%
Net Margin -6.48% 1.49% 0.22% -0.07% 6.82% 12.61%
Return on Equity (ROE) -16.09% 3.98% 0.58% -0.18% 20.66% 55.90%
Return on Assets (ROA) -11.22% 3.24% 0.43% -0.13% 15.20% 31.50%
Current Ratio 3.00× 4.42× 2.92× 3.39× 3.16× 1.95×
Debt-to-Equity 0.17× 0.05× 0.09× 0.14× 0.11× 0.42×
Effective Tax Rate -10.89% 60.81% 58.21% 134.00% -47.79% -10.57%
Cash Conversion Ratio -0.44× 2.56× 8.42× -36.24× 1.07× 0.38×
Accruals Ratio -0.16× -0.05× -0.03× -0.05× -0.01× 0.20×
SBC % of Revenue 0.44% 0.34% 0.50% 0.63% 0.66% 0.36%
CapEx Coverage 3.17× 10.38× 1.58× 8.16× 8.42× 8.24×
Free Cash Flow Per Share $0.03 $0.06 $0.01 $0.04 $0.11 $0.08

Income Statement

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Cost of Goods and Services Sold 43.07M 48.79M 46.43M 46.61M 49.69M 54.08M
Gross Profit 800.00K 5.56M 3.88M 4.06M 6.55M 9.48M
Selling, General and Administrative Expense 3.50M 3.54M 3.63M 3.94M 3.81M 3.70M
Operating Income (Loss) -2.71M 2.02M 251.00K 120.00K 2.75M 5.78M
Income Tax Expense (Benefit) 279.00K 1.25M 156.00K 134.00K -1.24M -766.00K
Net Income (Loss) Attributable to Parent -2.84M 808.00K 112.00K -34.00K 3.84M 8.01M
Earnings Per Share, Basic $-0.09 $0.03 $0.00 $0.00 $0.13 $0.27
Weighted Average Number of Shares Outstanding, Basic 31.06M 30.30M 30.07M 29.95M 29.84M 29.70M
Earnings Per Share, Diluted $-0.09 $0.03 $0.00 $0.00 $0.12 $0.25
Weighted Average Number of Shares Outstanding, Diluted 31.06M 31.17M 30.87M 29.95M 32.32M 32.11M

Balance Sheet

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Cash and Cash Equivalents, at Carrying Value 4.47M 3.62M 1.68M 1.32M 331.00K 210.00K
Assets, Current 17.38M 18.76M 17.88M 16.37M 16.63M 18.00M
Assets 25.34M 24.90M 26.21M 26.21M 25.25M 25.44M
Long-term Debt — — — 0 101.00K 3.64M
Liabilities, Current 5.80M 4.25M 6.12M 4.83M 5.26M 9.24M
Long-term Debt, Excluding Current Maturities — — — 7.00K 53.00K 0
Liabilities 7.67M 4.58M 6.97M 6.57M 6.67M 11.11M
Stockholders' Equity Attributable to Parent 17.67M 20.32M 19.24M 18.86M 18.57M 14.33M
Common Stock, Shares, Outstanding 31.06M 31.06M 30.10M 29.95M 29.95M 29.80M

Cash Flow Statement

Concept FY 2026FY 2025FY 2024FY 2023FY 2022FY 2021
Net Cash Provided by (Used in) Operating Activities 1.24M 2.06M 943.00K 1.23M 4.09M 3.05M
Payments to Acquire Property, Plant, and Equipment 346.00K 191.00K 553.00K 116.00K 486.00K 295.00K
Net Cash Provided by (Used in) Investing Activities -340.00K -205.00K -553.00K -111.00K -465.00K -199.00K
Net Cash Provided by (Used in) Financing Activities -45.00K 78.00K -29.00K -136.00K -3.50M -3.04M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (INBP CIK 0001016504), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

DSX

DIANA SHIPPING INC.

NBHC

NATIONAL BANK HOLDINGS CORP

VOR

Vor Biopharma Inc.